About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.

Correlation Between Autophagy-related Proteins and Inflammatory Markers in Hemodialysis Patients

Clinicaltrials.gov identifier NCT03925753

Recruitment Status Recruiting

First Posted April 24, 2019

Last update posted April 26, 2019

Study Description

Brief summary:

One recent study demonstrated impaired autophagy in patients receiving hemodialysis (HD). To clarify whether this alteration is related to the inflammatory state in HD patients, we focused on basal autophagy in peripheral blood mononuclear cells (PBMCs) of HD patients with and without inflammation and controls. PBMCs were harvested using Ficoll density gradient centrifugation . Levels of the autophagy‑associated proteins ubiquitin‑binding protein p62 (p62), microtubule‑associated proteins 1A/1B light chain 3A (LC3I/II) and beclin‑1 in PBMCs will be detected by western blotting. Enzyme‑linked immunosorbent assay kits will be used to detect the serum concentrations of interleukin (IL)‑6, liposaccharide-binding protein (LBP) and tumor necrosis factor (TNF)‑α.

  • Condition or Disease:Autophagy
  • Intervention/Treatment:
  • Phase: N/A
Detailed Description

Study Design and Population Study Design We shall enroll 30 healthy volunteers as the control group. 180 sex- and age-matched hemodialysis patients will be enrolled in this study. To be included in the study, patients have to be at least 20-years-old and on outpatient hemodialysis (HD) for at least 3 months. Patients are excluded if they had malignancy, severe liver disease (bilirubin >1.6 mg/dl), uncontrolled hypertension, severe obesity (BMI >35), currently on carbamazepine, statins or immunosuppressive agents. The medical record is thoroughly reviewed for each subject by a collaborating physician in the study. All subjects will provide written informed consent to participate and the protocol will be send to the institutional review boards of Tungs' Taichung Metroharbour Hospital Study Parameters Predialysis blood samples are obtained on a mid-week day. Within 30 min after sampling, the remaining blood is centrifuged at 3,000 g for 10 min, immediately aliquoted and frozen at -80°C until further analysis. Cytokine assays The following markers of inflammation and hemostasis are determined by ELISA in patients' sera: interleukin-6 (Quantikine, R&D Systems,) and plasma concentrations of CRP in a highly sensitive assay (hsCRP). Analysis of lipids/lipoproteins Total cholesterol, highdensity lipoprotein (HDL) cholesterol, and triglyceride concentrations are determined enzymatically. Plasma glucose is measured by a glucose-oxidase method. Measurements of Liposaccharide-binding protein (LBP) The LBP was determined from serum samples and controls using standardized enzymelinked immunosorbent assay (ELISA) methods, and serum from normal control subjects was used for interassay variation. Isolation of PBMCs Ethylenediamine tetraacetic acid Vacutainer™ tubes are used to collect venous blood samples (10 ml) from fasting participants in the early morning. Aliquots of the supernatant are collected by centrifugation at 800 x g and 25˚C for 15 min and subsequently store at ‑80˚C. The remaining blood is mixed and add slowly dropwise to a centrifuge tube containing 10 ml of Ficoll separation medium. PBMCs are isolated according to manufacturer's protocol and store at ‑80˚C. Western blotting PBMCs are lysed with RIPA lysis buffer and protein concentrations determined with the BCA Protein Assay kit according to the manufacturer's protocol. Subsequently, 20 μg of protein/well are separated using 12% SDS‑PAGE. The proteins are subsequently transferred to nitrocellulose membranes at 300 mA for 60 min. The nitrocellulose membranes are blocked with Tris‑buffered saline containing 0.1% Tween 20 (TBST) and 5% non‑fat milk powder for 2 h at room temperature. The nitrocellulose membranes are incubated with primary antibodies overnight at 4˚C on a shaker set at a slow speed. The nitrocellulose membranes are washed thrice with TBST and incubated with secondary antibodies for 1 h at room temperature. After washing thrice, ECL substrate is added to the nitrocellulose membrane. The signal is detected using Image Lab™ software and band density will be quantified with imager software . The primary antibodies against microtubule‑associated proteins 1A/1B light chain 3A , ubiquitin‑binding protein p62 and beclin‑1 as well as GAPDH will be purchased. Peroxidase‑conjugated goat anti‑mouse and goat anti‑rabbit secondary antibodies are used.

Study Design
  • Study Type: Observational
  • Estimated Enrollment: 210 participants
  • Observational Model: Case-Control
  • Time Perspective: Cross-Sectional
  • Official Title: Correlation Between Autophagy-related Proteins in Peripheral Blood Mononuclear Cells and Inflammatory Markers in Hemodialysis Patients
  • Actual Study Start Date: March 2019
  • Estimated Primary Completion Date: December 2019
  • Estimated Study Completion Date: December 2019
Outcome Measures
  • Primary Outcome Measures: 1. Levels of the autophagy‑associated proteins ubiquitin‑binding protein p62 (p62) [ Time Frame: 1 years ]
    ubiquitin‑binding protein p62 (p62) in PBMCs will be detected by western blotting.
  • 2. Levels of the autophagy‑associated proteins microtubule‑associated proteins 1A/1B light chain 3A (LC3I/II) [ Time Frame: 1 years ]
    microtubule‑associated proteins 1A/1B light in PBMCs will be detected by western blotting.
  • 3. Levels of the autophagy‑associated proteins beclin‑1 [ Time Frame: 1 years ]
    beclin‑1 in PBMCs will be detected by western blotting.
  • Secondary Outcome Measures: 1. Analysis of biomarkers of Liposaccharide-binding protein (LBP) [ Time Frame: 1 years ]
    The LBP was determined from serum samples and controls using standardized enzymelinked immunosorbent assay (ELISA) methods
  • 2. Analysis of biomarkers of IL-6 [ Time Frame: 1 years ]
    The IL-6 was determined from serum samples and controls using standardized enzymelinked immunosorbent assay (ELISA) methods was determined from serum samples and controls using standardized enzymelinked immunosorbent assay (ELISA) methods
  • 3. Measurements of TNF-α [ Time Frame: 1 years ]
    The TNF-α was determined from serum samples and controls using standardized enzymelinked immunosorbent assay (ELISA) methods
Eligibility Criteria
  • Ages Eligible for Study: 20 to 90 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes
  • Sampling Method: Probability Sample
  • Study Population: patients have to be at least 20-years-old and on outpatient hemodialysis (HD) for at least 3 months.
Criteria

Inclusion Criteria:

- Both sexes aged between 20-90 years.

- Received stable hemodialysis at least 3 months.

- Written informed consent.

Exclusion Criteria:

- patients with severe infections, severe heart disease and liver disease, malignancy,
autoimmune disorders, severe malnutrition, or clinical conditions requiring oral
nutrition supplements;

- Inability to follow protocol.

- Pregnancy or wishing/trying to get pregnant

Contacts and Locations
Contacts

Contact: Paik Seong Lim, PhD +886935045292 jamespslim@gmail.com

Locations

Taiwan
Tungs' Taichung MetroHarbour Hospital
Taichung

Sponsors and Collaborators

Tungs’ Taichung Metroharbour Hospital

Investigators

Study Chair: Paik Seong Lim, PhD Tungs’ Taichung Metroharbour Hospital

More Information
  • Responsible Party: Tungs’ Taichung Metroharbour Hospital
  • ClinicalTrials.gov Identifier: NCT03925753 History of Changes
  • Other Study ID Numbers: 107054
  • First Posted: April 24, 2019 Key Record Dates
  • Last Update Posted: April 26, 2019
  • Last Verified: April 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Tungs’ Taichung Metroharbour Hospital: autophagy inflammatory markers